Todd A. Black

Prior to joining the TB Alliance in early 2021 to focus on development of new therapies for tuberculosis, Todd was Executive Director for Merck’s Infectious Diseases and Vaccines Basic Research group. He has over 25 yrs of experience working on the discovery and development of novel therapies for infectious diseases at Novartis, Schering-Plough and Merck. Todd and his research teams have supported the discovery and development of a variety therapies for prevention and treatment of infectious diseases, including new classes of antibiotics, antifungals for invasive infections, HIV and HCV antivirals, new classes of agents for treating and preventing recurrent C. difficile infections, in addition to vaccines to prevent prevalent respiratory and invasive infections. Todd’s passion has been on the prevention and treatment of emerging pathogens including multi-drug resistant bacteria and other emerging pathogens. Todd earned his Ph. D. in Biochemistry at Michigan State University/DOE Plant Research Laboratory.